ClearPoint Neuro reports Q4 2022 revenue $5.2M (+21% YoY); full-year revenue $20.6M (+26% YoY)

ClearPoint Neuro, Inc.

2022-FY EPS reported -$0.68 revenue$20,551,000

Q4 2022 revenue $5.2M, up 21% YoY; full-year revenue $20.6M, up 26% YoY (record).
Biologics & drug delivery revenue $9.1M for 2022, up 34% YoY; over 50 partners.
Gross margin 66% for 2022 vs 68% in 2021; Q4 gross margin 64% vs 77%.
Cash & short-term investments $37.5M at Dec 31, 2022, down from $54.1M.
Reiterates 2023 revenue guidance $25-27M, expecting >20% growth.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

ClearPoint Neuro, Inc. reported the year ended December 31, 2022 results: revenue $20.6 million. Guidance reaffirmed.

Period: the year ended December 31, 2022
Revenue: $20.6 million
Guidance: reaffirmed
Result: reported results

Exact text from the filing

Total revenue was $20.6 million and $16.3 million for the years ended December 31, 2022 and 2021, respectively.

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

ClearPoint Neuro, Inc. reported the three months ended December 31, 2022 results: revenue $5.2 million.

Period: the three months ended December 31, 2022
Revenue: $5.2 million
Result: reported results

Exact text from the filing

Total revenue was $5.2 million for the three months ended December 31, 2022, and $4.3 million for the three months ended December 31, 2021, which represents an increase of $0.9 million, or 21%.

View on SEC.gov

Browse all earnings releases →

ClearPoint Neuro, Inc. filing history →

Source: SEC EDGAR

accession 0001285550-23-000019

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.